CytomX Therapeutics, Inc. (NASDAQ:CTMX) had its target price hoisted by Nomura to $44.00 in a research note released on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

CTMX has been the topic of a number of other reports. Wedbush started coverage on shares of CytomX Therapeutics in a report on Thursday, September 7th. They issued an outperform rating and a $26.00 target price on the stock. Jefferies Group LLC set a $25.00 target price on shares of CytomX Therapeutics and gave the stock a buy rating in a report on Friday, August 25th. ValuEngine downgraded shares of CytomX Therapeutics from a hold rating to a sell rating in a report on Friday, September 15th. Bank of America Corporation restated a buy rating and issued a $30.00 target price (up from $28.00) on shares of CytomX Therapeutics in a report on Wednesday, August 9th. Finally, BidaskClub upgraded shares of CytomX Therapeutics from a sell rating to a hold rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $32.67.

CytomX Therapeutics (CTMX) traded down 2.54% on Wednesday, hitting $21.50. 444,671 shares of the stock traded hands. The company’s 50 day moving average price is $17.37 and its 200-day moving average price is $15.69. The stock’s market cap is $792.64 million. CytomX Therapeutics has a 52-week low of $9.85 and a 52-week high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. On average, analysts forecast that CytomX Therapeutics will post ($1.47) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/nomura-boosts-cytomx-therapeutics-inc-ctmx-price-target-to-44-00/1615930.html.

In other CytomX Therapeutics news, major shareholder Robert I. Tepper sold 24,777 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sean A. Mccarthy sold 19,120 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the sale, the chief executive officer now directly owns 23,365 shares of the company’s stock, valued at $563,797.45. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 177,794 shares of company stock valued at $3,806,089. 4.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in CTMX. Legal & General Group Plc boosted its position in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the period. First Quadrant L P CA purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $160,000. Cubist Systematic Strategies LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $174,000. Goldman Sachs Group Inc. purchased a new stake in CytomX Therapeutics in the 1st quarter valued at about $190,000. Finally, Voya Investment Management LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $203,000. 59.97% of the stock is owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.